NIKKEI 225
26,393.04 -411.56 (-1.54%) HANG SENG
21,859.79 -137.10 (-0.62%) CRUDE OIL
106.01 -3.77 (-3.43%) GOLD FUTURES
1,808.00 -9.50 (-0.52%) DOW
30,775.43 -253.88 (-0.82%) BTC-GBP
15,527.83 -1,186.18 (-7.10%)
SENS Jul 2022 1.500 call
| Previous close | 1.4000 |
| Open | 1.6000 |
| Bid | 1.5000 |
| Ask | 1.7900 |
| Strike | 1.50 |
| Expiry date | 2022-07-15 |
| Day's range | 1.5500 - 1.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 47 |
- Business Wire
Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System
GERMANTOWN, Md., June 16, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy. The CE Mark approval confirms that the Eversense E3 meets the requirements of the
- Business Wire
Senseonics to Participate in the Jefferies Healthcare Conference
GERMANTOWN, Md., May 26, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
- Business Wire
Senseonics to Participate in the H.C. Wainwright Global Investment Conference
GERMANTOWN, Md., May 16, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference.
